Clinical Trials Logo

C3G clinical trials

View clinical trials related to C3G.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05809531 Active, not recruiting - C3 Glomerulopathy Clinical Trials

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

VALE
Start date: May 29, 2023
Phase: Phase 3
Study type: Interventional

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

NCT ID: NCT05067127 Active, not recruiting - C3 Glomerulopathy Clinical Trials

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

VALIANT
Start date: November 12, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.

NCT ID: NCT04572854 Active, not recruiting - Renal Transplant Clinical Trials

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

NOBLE
Start date: February 23, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.